- Stocks Telegraph
- Posts
- 19 Dec - NH - Morning Newsletter (with survey at top and bottom)
19 Dec - NH - Morning Newsletter (with survey at top and bottom)
4 Active Stocks Breaking Out Today
The Newsheater daily morning newsletter is powered by Stocks Telegraph
Help us improve newsletter by taking
Good Morning!Futures for US stock indices are rising on Thursday ahead of the release of final data on US GDP for the last quarter, according to trading data.Futures for the Dow Jones Industrial Index (DJIA) are growing by 0.13%, to 33611 points, futures for the NASDAQ high-tech index - by 0.19%, to 11355 points, and for the S&P 500 broad market index - by 0.13%, up to 3910.75 points.Analysts believe that US GDP in the third quarter, according to the third, final estimate, grew by 2.9% on an annualized basis (if GDP grew at the same rate for four consecutive quarters), as shown by the second estimate.At the same time, the publication of data on the number of initial applications for unemployment benefits for the week to December 17 is expected. Analysts suggest that the figure increased by 11,000 to 222,000 applications.
Breakthrough Carbon-Ion Technology EV Products 50X Faster
The global energy grid urgently needs an upgrade fast…Which could deliver a potential home-run for early stage investors in a breakthrough EV charging company by the name of Carbon-Ion.
Discover how you can get in on the ground floor level before it goes public and shares potentially soar!
Sponsored
Today Top Movers
ProQR Therapeutics N.V. (PRQR) stock soared 41.82% to $2.34 in the pre-market trading after announcing that its management will host an investor conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently announced partnership expansion with Lilly.
IsoPlexis Corporation (NASDAQ: ISO) shares are trading up 56.5% at $1.08 at the time of writing after announcing a definitive agreement with Berkeley Lights (BLI), under which Berkeley Lights will acquire IsoPlexis in an all-stock transaction valued at $57.8 million.
ORIC Pharmaceuticals Inc. (ORIC) grew over 47.0% at $4.41 in pre-market trading today. The company recently announced clinical development collaboration with Pfizer for ORIC-533 in multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer.
Alvotech (ALVO), a Drug Manufacturers - Specialty & Generic company, rose about 8.43% at $9.0 in pre-market trading Thursday following the declaration from the company that the FDA has granted a new Biosimilar User Fee Amendment (BsUFA) goal date of April 13, 2023, for Alvotech’s original Biologics License Application (BLA) for AVT02 as biosimilar to Humira®.
The Top 5 NASDAQ Stocks to Own for New Year 2023
Even in the worst of times, markets have rallied back. Just as they always have. So, if you're thinking of quitting the market, don't. There are plenty of bargains and hot investing ideas to jump on. In fact, here are five of our best ideas for 2023.
Sponsored
Top Upgrades & Downgrades
BofA turned bullish on Helen of Troy Limited (HELE), upgrading the stock to Buy from Neutral and assigning a $126 price target, representing potential upside of 29.56% from Wednesday's close.
Earlier Thursday Keefe, Bruyette & Woods reduced its rating on Jefferies Financial Group Inc. (JEF) stock to Market Perform from Outperform and assigned the price target to $37.
Canaccord Genuity analysts reduced their investment ratings, saying in research reports covered by the media that its rating for Coupa Software Incorporated (COUP) has been changed to Hold from Buy and the new price target is set at $81.
Analysts at Oppenheimer downgraded Celularity Inc. (CELU)'s stock to Perform from Outperform Thursday.
Hidden Income 'hack'
This hidden income strategy was just leaked and it can be yours now. It goes in depth about how you can start off with a small account and turn that into your own weekly paycheck. Learn how you can GAIN that extra advantage over what others aren't doing.
Sponsored
Latest Insider Activity
Ginkgo Bioworks Holdings Inc. (DNA) 10% Owner Canton Barry announced the sale of shares taking place on Dec 20 at $1.66 for some 408,767 shares. The total came to more than $676,509.
Snap Inc. (SNAP) Chief Financial Officer Andersen Derek sold on Dec 16 a total 57,281 shares at $8.47 on average. The insider’s sale generated proceeds of almost $0.48 million.
Cosmos Holdings Inc. (COSM) Chief Executive Officer Siokas Grigorios declared the purchase of shares taking place on Dec 19 at $11.50 for some 260,870 shares. The transaction amount was around $3.0 million.
Aytu BioPharma Inc. (AYTU) Chief Executive Officer Disbrow Joshua R. bought on Dec 19 a total 112,371 shares at $0.22 on average. The purchase cost the insider an estimated $25,047.
Early Profit-Advantage on 50-cent Uranium Stock as Prices Soar
Uranium prices are soaring as more than HALF of global uranium production has been taken offline. Investors are lining up for gains and it could be the windfall of a lifetime. The last time we saw something like this, the price of uranium roared all the way to $140.
Sponsored
Important Earnings
Top US earnings releases scheduled for today include CarMax Inc. (NYSE:KMX). It will announce its Nov 2022 financial results. The company is expected to report earnings of $0.7 per share from revenues of $7.28B in the three-month period.
Analysts expect Paychex Inc. (NASDAQ:PAYX) to report a net income (adjusted) of $0.95 per share, when the company releases its quarterly results shortly. Revenue for the fiscal quarter ended Nov 2022 is predicted to come in at $1.19B.
Mission Produce Inc. (AVO), due to announce earnings after the market closes today, is expected to report earnings of $0.34 per share from revenues of $250.03M recently concluded three-month period.
That's it for today. Thanks for reading. Good luck out there!Best Regards,Stocks Telegraph Team
P.S. Want my daily watchlists sent to your cell phone too? Just go HERE and join my text message list!
Wouldn’t it be great to have a personalized solution for your investing needs? We’re adding new sections to the morning newsletter with big implications. All you have to do is share your thought about the current newsletter. If you do that, we’ll do our best to take your feedback and make it a better experience for you.
We are asking for 1 minute of your time to answer 4 questions about your experience with our newsletter. We hope to use this information to create solutions that address exactly what you need!
Thank you for your continued support.
Disclaimer: Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside of these emails.